ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Fighting Heartburn and Gerd Naturally – And Safely!

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

Natural Bladder Control, Go Less and Live More

Top Vitamin and Mineral Deficiencies — Are You at Risk?

Trimming the spare tire: Canola oil may cut belly fat

How Pomegranate May Protect Against Cancer

Omega Fix for Obesity: How the Right Fats Fight Fat

Curcumin Reverses the Cellular Damage of Chronic Stress

Probiotics improve cognition in Alzheimer's patients

The Onion: Cancer Fighter and Food Preserver

 
Print Page
Email Article

Androclus Therapeutics Announces Publication of Phase I/IIa Rheumatoid Arthritis Clinical Trial Results

  [ 53 votes ]   [ Discuss This Article ]
www.ProHealth.com • May 14, 2004


SAN DIEGO & MILAN, Italy--(BUSINESS WIRE)--May 14, 2004--

Androclus Therapeutics announced publication of Phase I/IIa clinical trial results of its AT-001 (dnaJP1) compound for treatment of rheumatoid arthritis (RA) in Proceedings of the National Academy of Sciences*. The product, developed at University of California, San Diego, demonstrated biological efficacy, with no significant side effects observed. The AT-001 (dnaJP1) compound is a short, engineered oral peptide with disease-specific immunomodulatory activity. It is a revolutionary biologic that is intended to induce tolerization of the auto immune process in patients with RA, thus inhibiting disease-related inflammation without affecting patient's immunity to infection or cancer.

During the clinical trial, patients with early RA were treated with AT-001 orally for 6 months. The peptide caused no side effects and induced a change from pro inflammatory to regulatory T cell function. Peptide-induced T cell production of IL-4 and IL-10 increased significantly as a result of the treatment, while peptide-induced T cell proliferation and production of IL-2, interferon-gamma and TNF-alpha decreased significantly. Responses to unrelated antigens did not change, confirming the antigen-specific nature of this treatment.

The trial design was open-label and a placebo control was not included. In this open-label context, both physician- and patient-generated clinical scores showed marked improvement from baseline. AT-001 is currently the subject of a multi-center Phase II clinical trial for RA, sponsored by NIH.

Immunomodulation therapy such as AT-001 may be particularly helpful in delaying or possibly abolishing the need for disease modifying antiarthritic drugs (DMARDs), which provide significant improvements in RA, but have potentially serious side effects. Compared to the current generation of anti-inflammatory biologics, AT-001 is intended to have specific and not broadly immunosuppressive action, is oral and has to-date demonstrated a very favorable side-effect profile.

This immunomodulation therapy was developed at University of California, San Diego by Salvatore Albani, M.D., Ph.D., Professor of Medicine and Pediatrics and coworkers. The discovery was supported by previous studies by Dr. Albani and Dr. Dennis Carson, UCSD Professor of Medicine. The University of California has licensed to Androclus Therapeutics exclusive rights to further develop such immunomodulation therapies for RA and other indications. Dr. Albani is the scientific founder of Androclus Therapeutics.

The immunomodulatory approach pioneered by AT-001 is applicable to the treatment of a broad range of auto-immune diseases. Androclus is currently developing therapeutics for the treatment of multiple sclerosis and inflammatory bowel disease, with Phase I/IIa clinical trials expected to start in early 2005.

About Androclus Therapeutics Androclus Therapeutics is a private biotechnology company with a mission to discover, develop and bring to commercial fruition novel products and technologies for treatment of diseases involving the immune system, such as auto-immunity, cancer and infectious diseases. Androclus' revolutionary technology platform enables up- or down-modulation of patients' immune responses, without the broad immunosuppression associated with currently marketed anti-inflammatory drugs. Androclus' R&D portfolio includes oral therapeutic peptides for the treatment of rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.

For more information, visit Androclus' Web site at www.androclus.com. *Prakken, B.J., R. Samodal, F. Giannoni, G.L. Puga Yung, J.F. Scavulli, A. Amox, S. Roord, I. De Kleer, D. Bonnin, P. Lanza, C. Berry, M. Massa, R. Billetta, and S. Albani. 2004. Epitope-specific immunotherapy induces immune deviation of pro-inflammatory T cells in Rheumatoid Arthritis. Proceedings of the National Academy of Sciences, March 23, 2004, Vol. 101, No. 12, pages 4228-4233.



Post a Comment

Featured Products From the ProHealth Store
Ultra ATP+, Double Strength Ultra EPA  - Fish Oil Energy NADH™ 12.5mg


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

How I Found My Long-Lost Energy How I Found My Long-Lost Energy
Block food Cravings At Their Molecular Root Block food Cravings At Their Molecular Root
Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial
Astaxanthin - A Little-Known but Power-Packed Nutrient Astaxanthin - A Little-Known but Power-Packed Nutrient
Enhance Eyelashes Naturally Enhance Eyelashes Naturally

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map